SAN FRANCISCO – Bispecific antibodies, expected as a class to carve out a multibillion-dollar niche in the decade ahead, continue to face multiple challenges between now and then. However, with significant clinical investment, the approach is gaining momentum, company executives said at the BIO Investor Forum in San Francisco on Monday.